GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Sponsor
Canadian Cancer Trials Group
Study ID
NCT07297667
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fludarabine — DRUG
    Assigned at enrollment
  • Cyclophosphamide — DRUG
    Assigned at enrollment
  • GCAR1 — BIOLOGICAL
    Dose escalation

Study Details

Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers

Key Dates

First listed
Dec 22, 2025
Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Dec 1, 2028
Completion
Sep 1, 2033

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: GCAR1 Infusion

Primary Outcome Measure

To determine the recommended phase II dose (RP2D), defined as the next lower dose below the maximum administered dose, of GPNMB directed CAR T cell therapy [ Time Frame: 3 years ]

Central Contacts

Find similar trials

Nationwide
Kidney cancer trialsBreast cancer trialsOncology trialsUrology trialsBreast oncology trialsWomen's health trials

Related Studies